Education
About Us
Working with TipRanks
Follow Us
Enorama Pharma AB (SE:ERMA)
:ERMA
Top Page
Enorama Pharma AB
(ERMA)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr2.00
▲(4.71% Upside)
The score is driven primarily by weak financial performance, including sharply lower TTM revenue, ongoing losses, negative equity, and significant cash burn. Technicals also remain bearish with price below major moving averages and a negative MACD. Valuation is constrained by negative earnings (negative P/E) and no dividend yield data.
Enorama Pharma AB (ERMA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr149.92M
Dividend YieldN/A
Average Volume (3M)4.35K
Price to Earnings (P/E)―
Beta (1Y)0.58
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees5
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.18
Shares Outstanding74,588,684
10 Day Avg. Volume2,975
30 Day Avg. Volume4,348
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)22.84
Price to Sales (P/S)11.30
P/FCF Ratio-4.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Enorama Pharma AB Business Overview & Revenue Model
Company DescriptionEnorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. It offers nicotine chewing gum for smoking cessation and medical cannabis chewing gums for non-pharma applications, as well as for other applications, such as oromucosal drug delivery and allergic rhinitis. The company is based in Malmö, Sweden.
How the Company Makes Money
Enorama Pharma AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.63M | 15.77M | 1.36M | 6.85M | 11.04M | 2.15M |
| Gross Profit | -23.84M | 3.70M | -3.90M | -616.00K | 2.13M | 2.37M |
| EBITDA | -47.98M | -20.41M | -43.05M | -37.22M | -26.28M | -22.69M |
| Net Income | -76.57M | -43.81M | -44.61M | -41.78M | -28.54M | -23.90M |
Balance Sheet | ||||||
| Total Assets | 12.57M | 15.89M | 34.38M | 48.72M | 50.93M | 40.91M |
| Cash, Cash Equivalents and Short-Term Investments | 6.56M | 2.08M | 6.15M | 4.14M | 12.20M | 4.73M |
| Total Debt | 0.00 | 0.00 | 436.00K | 1.91M | 3.79M | 5.71M |
| Total Liabilities | 17.22M | 8.09M | 14.85M | 17.20M | 29.58M | 39.13M |
| Stockholders Equity | -4.65M | 7.80M | 19.54M | 31.52M | 21.35M | 1.78M |
Cash Flow | ||||||
| Free Cash Flow | -47.77M | -35.70M | -41.35M | -32.96M | -31.99M | -26.83M |
| Operating Cash Flow | -47.77M | -35.70M | -41.35M | -32.96M | -30.16M | -23.00M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -1.82M | -3.84M |
| Financing Cash Flow | 40.87M | 35.29M | 41.86M | 25.34M | 39.51M | 16.96M |
Enorama Pharma AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:ERMA
Enorama Pharma AB
2.01
-1.48
-42.41%
DE:AC6
AlzeCure Pharma AB
0.13
0.05
59.26%
DE:OMAX
Vivesto AB
0.02
0.00
0.00%
DE:6FN
Klaria Pharma Holding AB
0.06
0.04
180.00%
DE:40M
Nanexa AB
0.31
0.15
86.83%
SE:ENZY
Enzymatica AB
2.05
0.44
27.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.